



## 3.4.9 Diagnóstico y tratamiento de las enfermedades alérgicas

Publicaciones: 49

Factor Impacto: 298.<sup>392</sup>

Q1: 20



## Actividad de Investigación

## Tesis doctorales

**Pola Pola B.** Exacerbaciones de asma en el servicio de urgencias del Hospital Universitario La Paz [dissertation]. Madrid: UAM: 2020(43868).

**Directores:** Quirce Gancedo S, Álvarez-Sala Walther R.

## Publicaciones

- Agache I, Beltrán J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Makela M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, de Llano LP, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M. Efficacy and safety of treatment with biologicals

(benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. *Allergy*. 2020; 75(5): 1023-42. Article. IF: 13.146; D1

- Agache I, Rocha C, Beltrán J, Song Y, Posso M, Sola I, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Makela M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, de Llano LP, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. *Allergy*. 2020; 75(5): 1043-57. Article. IF: 13.146; D1
- Agache I, Song Y, Rocha C, Beltrán J, Posso M, Steiner C, Alonso-Coello P, Akdis C, Akdis M,

Canonica GW, Casale T, Chivato T, Corren J, del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Makela M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, de Llano LP, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. *Allergy*. 2020; 75(5): 1058-68. Review. IF: 13.146; D1

- Balas A, Ramírez E, Trigo E, Cabañas R, Fianador A, Arsuaga M, Lerma V, Sanz B, LuisVicario J, Herranz P, de Abajo F, Bellón T. HLA-A\*68, -A\*11:01, and -A\*29:02 alleles are strongly associated with benznidazole-induced maculopapular exanthema (MPE)/DRESS. *J Allergy Clin Immunol-Pract*. 2020; 8(9): 3198-200. Letter. IF: 8.861; Q1
- Busse WW, Maspero JF, Lu YF, Corren J, Hana-

nia NA, Chipps BE, Katelaris CH, FitzGerald JM, Quirce S, Ford LB, Rice MS, Kamat S, Khan AH, Jagerschmidt A, Harel S, Rowe P, Pirozzi G, Amin N, Ruddy M, Graham NMH, Teper A. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. *Ann Allergy Asthma Immunol*. 2020; 125(5):565-576. Article. IF: 6.347; Q1

- Caballero ML, Quirce S. Delayed hypersensitivity reactions caused by drug excipients: A literature review. *J Invest Allergol Clin Immunol*. 2020; 30(6): 400-8. Review. IF: 4.333; Q2
- Caballero ML, Quirce S. Immediate hypersensitivity reactions caused by drug excipients: A literature review. *J Invest Allergol Clin Immunol*. 2020; 30(2): 86-100. Review. IF: 4.333; Q2
- Cabrejas S, Moreira A, Ramírez A, Quirce S, Campos GS, Davila I, Campo P. FENOMA study: Achieving full control in patients with severe allergic asthma. *J ASTHMA ALLERGY*. 2020; 13: 159-66.



## 3.4 Patologías de Grandes Sistemas

- Article. IF: 4.258; Q2
- Córdón JP, Pallares PD, Molina TC. Ultrasound findings in an abdominal crisis of a patient with hereditary angioedema. *Rev Esp Enferm Dig.* 2020; 112(5): 418. Letter. IF: 2.086; Q4
  - Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan AH, Kamat S, Maroni J, Rowe P, Lu YF, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. *J Allergy Clin Immunol-Pract.* 2020; 8(2): 516-26. Article. IF: 8.861; Q1
  - Corvillo F, de la Morena-Barrio ME, Marcos-Bravo C, López-Trascasa M, Vicente V, Emsley J, Caballero T, Corral J, López-Lera A. The FXII c.-4T > C Polymorphism as a disease modifier in patients with hereditary angioedema due to the FXII p.Thr328Lys variant. *Front Genet.* 2020; 11: 1033. Article. IF: 4.599; Q2
  - Domínguez-Ortega J, López-Carrasco V, Barranco P, Ifim M, Luna JA, Romero D, Quirce S. Early experiences of SARS-CoV-2 infection in severe asthmatics receiving biologic therapy. *J Allergy Clin Immunol-Pract.* 2020; 8(8): 2784-6. Letter. IF: 8.861; Q1
  - Domínguez-Ortega J, Navarro A, Romero JD, Dordal T, Habernau A, Rodríguez M, Mur-Gimeno P, Gutiérrez MLG, Pérez-Frances C, Miravalles MJP, Colas C, Davila I, Fernández FR, Hernández MCS, Valero A. Pollen-induced allergic asthma and rhinoconjunctivitis: Differences in outcome between seasonal and nonseasonal exposure to allergens under real-life conditions (The LANDSCAPE Study). *J Invest Allergol Clin Immunol.* 2020; 30(6): 454-6. Editorial Material. IF: 4.333; Q2
  - Domínguez-Ortega J, Sáez-Martínez FJ, Gómez-Saenz JT, Molina-Paris J, Álvarez-Gutiérrez FJ. The management of asthma as a chronic inflammatory disease and global health problem: A position paper from the scientific societies. *Med Fam-SEMERGEN.* 2020; 46(5): 347-54. Article. Not Indexed
  - García-Boyano M, Gómez-Traseira C, Umpiérrez AM, Quirce S, Boyano-Martínez T. Drug provocation tests for assessing antibiotic hypersensitivity is shorter also better? *Pediatr Infect Dis J.* 2020; 39(9): 835-9. Article. IF: 2.129; Q3
  - Germanis AE, Margaglione M, Pesquero JB, Farkas H, Cichon S, Csuka D, Lera AL, Rijavec M, Jolles S, Szilagyí A, Trascasa ML, Veronez CL, Drouet C, Zamanakou M. International consensus on the use of genetics in the management of hereditary angioedema. *J Allergy Clin Immunol-Pract.* 2020; 8(3): 901-11. Article. IF: 8.861; Q1
  - Grabenhenrich L, Trendelenburg V, Bellach J, Yurek S, Reich A, Fiandor A, Rivero D, Sigurdardottir S, Clausen M, Papadopoulos NG, Xepapadaki P, Sprickelman AB, Dontje B, Roberts G, Grimshaw K, Kowalski ML, Kurowski M, Dubakiene R, Rudzeviciene O, Fernández-Rivas M, Couch P, Versteeg SA, van Ree R, Mills C, Keil T, Beyer K. Frequency of food allergy in school-aged children in eight European countries-The EuroPrevall-iFAAM birth cohort. *Allergy.* 2020; 75(9): 2294-308. Article. IF: 13.146; D1
  - Grimshaw KEC, Roberts G, Selby A, Reich A, Butiene I, Clausen M, Dubakiene R, Fiandor A, Fiocchi A, Grabenhenrich LB, Larco JI, Kowalski ML, Rudzeviciene O, Papadopoulos NG, Rosenfeld L, Sigurdardottir ST, Sprickelman AB, Schoemaker AA, Xepapadaki P, Mills ENC, Keil T, Beyer K. Risk factors for Hen's egg allergy in Europe: EuroPrevall Birth Cohort. *J Allergy Clin Immunol-Pract.* 2020; 8(4): 1341-8. Article. IF: 8.861; Q1
  - Howarth P, Quirce S, Papi A, Israel E, Mallett S, Bates S, Yancey S, Albers FC, Kwon N. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma. *Allergy.* 2020; 75(8): 2085-8. Letter. IF: 13.146; D1
  - Janson C, Menzies-Gow A, Nan C, Nuevo J, Papi A, Quint JK, Quirce S, Vogelmeier CF. SABINA: An overview of short-acting beta(2)-agonist use in asthma in European countries. *Adv Ther.* 2020; 37(3): 1124-35. Article. IF: 3.845; Q2
  - Klug C, Hemmer W, Román-Carrasco P, Focke-Tejkl M, Quirce S, Boyano-Martínez T, Gaubitzer E, Wank H, Swoboda I. Gal d 7-a major allergen in primary chicken meat allergy. *J Allergy Clin Immunol.* 2020; 146(1): 169-79. Article. IF: 10.793; D1
  - Lazzarato I, González-Muñoz M, Heredia R, Castellar FR, de la Guía AL, Cabañas R, Fiandor A, Domínguez-Ortega J. Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT. *Eur Ann Allergy Clin Immunol.* 2020; 52(5): 235-7. Letter. Not Indexed
  - Levy D, Caballero T, Hussain I, Reshef A, Anderson J, Baker J, Schwartz LB, Cicardi M, Prusty S, Feuersenger H, Pragst I, Manning ME. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. *Pediatr Allergy Immunol Pulmonol.* 2020; 33(3): 136-41. Article. IF: 1.349; Q4
  - Loli-Ausejo D, Hernández-Martín I, Cabañas R, Entrala A, Gutiérrez-Alvarino M, Martínez-Sánchez N, Caballero T. Tranexamic acid plus bemparin sodium as long-term prophylaxis in a patient with FXII-HAE during pregnancy: A case report. *J Invest Allergol Clin Immunol.* 2020; 30(6): 464-5. Editorial Material. IF: 4.333; Q2
  - Loli-Ausejo D, Vilchez-Sánchez F, Gómez-Traseira C, Tomás-Pérez M, González-Muñoz M. Fixed food eruption caused by peanut confirmed by open oral food challenge and in vitro cellular testing. *Contact Dermatitis.* 2020; 83(3): 227-9. Editorial Material. IF: 6.6; D1
  - Marqués-Mejías MA, Tomás-Pérez M, Vila-Nadal G, Quirce S. Acute urticaria in the pediatric emergency department Management and possible triggers. *Ann Allergy Asthma Immunol.* 2020; 124(4): 396-7. Letter. IF: 6.347; Q1
  - Maurer M, Aberer W, Agondi R, Al-Ahmad M, Al-Nesf MA, Anotegui I, Arnaout R, Arruda LK, Asero R, Aygoren-Pursu E, Banerji A, Bauer A, Ben-Shoshan M, Berardi A, Bernstein JA, Betschel S, Bindslev-Jensen C, Bizjak M, Boccon-Gibod I, Bork K, Bouillet L, Boysen HB, Brodzki N, Broesby-Olsen S, Busse P, Buttgereit T, Bygum A, Caballero T, Campos RA, Cancian M, Cherrez-Ojeda I, Cohn DM, Costa C, Craig T, Criado PR, Criado RF, Csuka D, Dissemond J, Du-Thanh A, Ensina LF, Ertas R, Fabiani JE, Fantini C, Farkas H, Ferrucci SM, Figueras-Nart I, Fili NL, Fomina D, Fukunaga A, Gelincik A, Giménez-Arnau A, Godse K, Gompels M, Goncalo M, Gotua M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Iliina N, Inomata N, Jakob T, Josviack DO, Kang HR,
  - Kaplan A, Kasperska-Zajac A, Katelaris C, Kessel A, Kleinheinz A, Kocatürk E, Kosnik M, Krawowska D, Kulthanan K, Kumaran MS, Sousa JIL, Longhurst HJ, Lumry W, MacGinnitie A, Magerl M, Makris MP, Malbran A, Marsland A, Martínez-Saguer I, Medina IV, Meshkova R, Metz M, Nasr I, Nicolay J, Nishigori C, Ohsawa I, Ozyurt K, Papadopoulos NG, Parisi CAS, Peter JG, Pflutzner W, Popov T, Prior N, Ramon GD, Reich A, Reshef A, Riedl MA, Ritchie B, Rockmann-Helmbach H, Rudenko M, Salman A, Sánchez-Borges M, Schmid-Grendelmeier P, Serpa FS, Serra-Baldrich E, Sheikh FR, Smith W, Soria A, Staubach P, Steiner UC, Stobiecki M, Sussman G, Tagka A, Thomsen SF, Treudler R, Valle S, van Doorn M, Varga L, Vázquez DO, Wagner N, Wang LC, Weber-Chrysochoou C, Ye YM, Zalewska-Janowska A, Zanichelli A, Zhao ZT, Zhi YX, Zuberbier T, Zwiener RD, Castaldo A. Definition, aims, and implementation of GA(2)LEN/HAEi angioedema centers of reference and excellence. *Allergy.* 2020; 75(8): 2115-23. Letter. IF: 13.146; D1
  - Moral VP, Gómez-Outes A, Gancedo SQ, Alobid I, Rodríguez CA, Aparicio MB, García G, Ruiz FG, Requena AH, Murua JK, París JM, Belinchon FJP, Encinas MP, Zamora JP, Crespo MP, Pina CS, Ortega JS. Discrepancies between GEMA and GINA in the classification of inhaled corticosteroids. *Arch Bronconeumol.* 2020; 56(7): 472-3. Letter. IF: 4.872; Q2
  - Moscato G, Apfelbacher C, Brockow K, Eberle C, Genuneit J, Mortz CG, Quecchia C, Quirce S, Siracusa A, Tarlo SM, van Kampen V, Walusiak-Skorupa J, Raulf M. Gender and occupational allergy: Report from the task force of the EAACI Environmental and Occupational Allergy Interest Group. *Allergy.* 2020; 75(11): 2753-63. Article. IF: 13.146; D1
  - Pedrosa M, Guerrero-Sánchez VM, Canales-Bueno N, Loli-Ausejo D, Castillejo MA, Quirce S, Jorrián-Novo JV, Rodríguez-Pérez R. Quercus ilex pollen allergen, Que i 1, responsible for pollen food allergy syndrome caused by fruits in Spanish allergic patients. *Clin Exp Allergy.* 2020; 50(7): 815-23. Article. IF: 5.018; Q2
  - Pinera-Salmerón P, Álvarez-Gutiérrez FJ, Domínguez-Ortega J, Álvarez C, Blanco-Aparicio M, Dávila I, López-Vina A, Miguens I, Soto-Retes L.



### 3.4 Patologías de Grandes Sistemas

- Referral recommendations for adult emergency department patients with exacerbated asthma. *Emergencias*. 2020; 32(4): 258-68. Article. IF: 3.881; Q1
- Plaza V, del Cuvillo A, Soto-Retes L, Gras JR, Cisneros C, Sánchez-Cuellar S, Gómez-Bastero A, Martínez-Moragón E, Sabadell C, Quirce S, Álvarez F, Rosado A, Lluch I, Soto G. Functional endoscopic sinus surgery for nasal polyposis in asthma patients: Impact on bronchial inflammation. *Arch Bronconeumol*. 2020; 56(6): 403-5. Letter. IF: 4.872; Q2
  - Quirce S, Heffler E, Nenashva N, Demoly P, Menzies-Gow A, Moreira-Jorge A, Nissen F, Hanania NA. Revisiting late-onset asthma: Clinical characteristics and association with allergy. *J Asthma Allergy*. 2020; 13: 743-52. Review. IF: 4.258; Q2
  - Román-Carrasco P, Hemmer W, Klug C, Friedrich A, Stoll P, Focke-Tejkl M, Altmann F, Quirce S, Swoboda I. Individuals with IgE antibodies to alpha-Gal and CCD show specific IgG subclass responses different from subjects non-sensitized to oligosaccharides. *Clin Exp Allergy*. 2020; 50(9): 1107-10. Letter. IF: 5.018; Q2
  - Ruiz-Hornillos J, Jiménez BR, Vila AF, Fernández AM, García MJH, Domínguez-Ortega J. Omalizumab as a therapeutic option for nasal polyposis in moderate-to-severe persistent allergic asthma: Evidence from a prospective study in a real-world setting. *J Invest Allergol Clin Immunol*. 2020; 30(6): 470-2. Editorial Material. IF: 4.333; Q2
  - Sánchez-García S, Rial MJ, Domínguez-Ortega J. Long and winding road: from infant wheeze to adult asthma. *Curr Opin Pulm Med*. 2020; 26(1): 3-9. Review. IF: 3.155; Q3
  - Sigsgaard T, Basinas I, Doekes G, de Blay F, Folletti I, Heederik D, Lipinska-Ojrzanowska A, Nowak D, Olivieri M, Quirce S, Raulf M, Sastre J, Schlunssen V, Walusiak-Skorupa J, Siracusa A. Respiratory diseases and allergy in farmers working with livestock: a EAACI position paper. *Clin Transl Allergy*. 2020; 10(1): 29. Review. IF: 5.871; Q2
  - Suojalehto H, Suuronen K, Cullinan P, Lindstrom I, Sastre J, Walusiak-Skorupa J, Muñoz X, Talini D, Klusackova P, Moore V, Merget R, Svanes C, Mason P, Dell'Omo M, Moscato G, Quirce S, Hoyle J, Sherson D, Preisser A, Seed M, Riffart C, Godet J, de Blay F, Vandenplas O. Phenotyping occupational asthma caused by acrylates in a multicenter cohort study. *J Allergy Clin Immunol-Pract*. 2020; 8(3): 971-9. Article. IF: 8.861; Q1
  - Tarlo SM, Quirce S. Impact of identification of clinical phenotypes in occupational asthma. *J Allergy Clin Immunol-Pract*. 2020; 8(10): 3277-82. Review. IF: 8.861; Q1
  - Tomás-Pérez M, Gómez-Traseira C, González-Muñoz M, Quirce S. Adverse reaction with hexavalent vaccine: An unusual case. *Allergol Immunopath*. 2020; 48(6): 801-3. Article. IF: 1.667; Q4
  - Tomás-Pérez M, Domínguez-Ortega J. Pemphigoid reaction by specific allergen immunotherapy: An unusual adverse reaction. *J Invest Allergol Clin Immunol*. 2020; 67(1): 83-6. Article. Not Indexed
  - Urrutia I, Delgado J, Domínguez-Ortega J, Mascaros E, Pérez M, Resler G, Plaza V, Flor X, Vega JM, Martínez GL, Fernández JP, Muñoz X, Roger A, Navarro EM, Gómez E, Adrados ACG, Pérez RG, Pérez JMH, Barcala FJG, Rey JG, Bobolea ID, García SS, Saenz JTG, Cebollera P, Vina AL, Moragon EM, Valero A, Campos RD, Talavera IG, Viteri SA, Robaina JCG, Arrondo AP. Clinical factors associated with overuse of asthma reliever medication. *J Invest Allergol Clin Immunol*. 2020; 30(1): 42-8. Article. IF: 4.333; Q2
  - Vicente F, Sanchiz A, Rodríguez-Pérez R, Pedrosa M, Quirce S, Haddad J, Besombes C, Linacero R, Allaf K, Cuadrado C. Influence of instant controlled pressure drop (DIC) on allergenic potential of tree nuts. *Molecules*. 2020; 25(7): 1742. Article. IF: 4.411; Q2
  - Vilchez-Sánchez F, Domínguez-Ortega J, Muñoz MG, Loli-Ausejo D, Heredia-Revuelto R, Román AF, Quirce S. Two case reports of delayed-allergic reactions to clindamycin confirmed with a positive lymphocyte transformation test. *Eur Ann Allergy Clin Immunol*. 2020; 52(2): 91-3. Article. Not Indexed
  - Vilchez-Sánchez F, Loli-Ausejo D, Rodríguez-Mariblanca A, Montserrat-Villatoro J, Ramírez E, Domínguez-Ortega J, González-Muñoz M. Lymphocyte transformation test can be useful for the diagnosis of delayed adverse reactions to sulfonamides. *Allergy*. 2020; 75(12): 3267-72. Letter. IF: 13.146; D1
  - Villamañán E, Herrero A, Álvarez-Sala R, Quirce S. Multidisciplinary severe asthma management: The role of hospital pharmacists in accredited specialized adult asthma units in Spain. *J Invest Allergol Clin Immunol*. 2020; 30(4): 305-6. Letter. IF: 4.333; Q2
  - Wanden-Berghe C, Compes CC, Jiménez MIM, Cunill JLP, Boluda ER, Candela CG, Casas NV, Pelaez RB, Román DAD, Lázaro MAP, Martos EAS, Faedo CM, Guardiola PD, Hernández JA, Murillo AZ, Martín CC, Paris AS, Fontalba MDM, Lobo G, Martín PM, Pérez FC, Folgueras TM, Palmero MAM, Pérez LML, Burdiel OSV, Costa CM, Pérez CT, Ramírez MJM, Delgado YG, González MAP, Roca SM, Zafra MVG, Díaz MG, Gabino VR, Baeza BM, Marín MG, Rocamora JAI, Sánchez RS, Celaya AA, Ortiz CJ, Llanos JPS, de la Maza BP, García PL, Martínez MCG, Santaliestra MJC. Home and ambulatory artificial nutrition (NAD-YA) group report. Home parenteral nutrition in Spain, 2018. *Nutr Hosp*. 2020; 37(2): 403-7. Article. IF: 1.057; Q4
  - Wardlaw A, Howarth PH, Israel E, Taille C, Quirce S, Mallett S, Bates S, Albers FC, Kwon N. Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma. *Clin Exp Allergy*. 2020; 50(7): 869-72. Letter. IF: 5.018; Q2
  - Zamarrón E, Romero D, Fernández-Lahera J, Villasante C, Piniña I, Barranco P, Domínguez-Ortega J, Walther RAS. Should we consider paranasal and chest computed tomography in severe asthma patients? *Respir Med*. 2020; 169: 106013. Article. IF: 3.415; Q2
- lity of life study (DTV-IHAE-QOL) (PI-281). AEDAF. 2009-Ongoing.
- Centro de gestión:** FIBHULP
- Caballero Molina MT.** Estudio de las características clínicas y fisiopatológicas del angioedema sin habones (PI19/01434). ISCIII. 2020-2022.
- Centro de gestión:** FIBHULP
- Caballero Molina MT.** Humanistic and economic burden of hereditary angioedema in Spain (Carga económica y humanística del angioedema hereditario en España). Shire-Takeda. 263.480€. PI: 4674. (IIR-ESP-002527. PI: 4674). Shire-Takeda. 2019-Ongoing.
- Centro de gestión:** FIBHULP
- Caballero Molina MT.** Nuevos biomarcadores en enfermedades mediadas por el sistema del complemento (PI15/00255). ISCIII. 2016-2020.
- Centro de gestión:** FIBHULP
- Domínguez Ortega FJ.** Asesoramiento para el diseño del estudio clínico Ensayo clínico prospectivo multicéntrico aleatorizado de doble simulación controlado con placebo de búsqueda de la dosis más eficaz para el tratamiento de rinitis/rinokonjuntivitis por alergia frente al polen gramíneas. Inmunotek. 2015-Ongoing.
- Centro de gestión:** FIBHULP
- Domínguez Ortega FJ.** Estudio de coste-efectividad de mepolizumab en pacientes con asma grave no controlada en condiciones de vida-real. Glaxosmithkline S. A. 2021-Ongoing.
- Centro de gestión:** FIBHULP
- Quirce Gancedo S.** Programa de la unidad multidisciplinar de asma grave de La Paz: de la investigación a la práctica clínica. Astrazeneca Farmacéutica Spain S. A. 2019-Ongoing.
- Centro de gestión:** FIBHULP

### Proyectos de investigación

**Caballero Molina MT.** Development and trans-cultural validation of an international specific questionnaire (IHAE-QOL) for assessment of health related quality of life in adult patients with hereditary angioedema due to c1 inhibitor deficiency (HAE) and qua-



**Quirce Gancedo S.** Relación entre asma y obesidad en la población española mayor o igual a 18 años. Novartis Farmacéutica S. A. 2009-Ongoing.

**Centro de gestión:** FIBHULP

**Quirce Gancedo S.** Sesiones en investigación del diagnóstico molecular como herramienta de identificación de perfiles de respuesta en pacientes con enfermedad respiratoria alérgica y alergia a alimentos. Thermo Fisher Diagnostics S. L. U. 2017-Ongoing.

**Centro de gestión:** FIBHULP

**Quirce Gancedo SE, Fiandor Román AMC.** Plan de formación de la unidad de asma grave del Hospital Universitario La Paz: de la investigación a la práctica clínica. AstraZeneca Farmacéutica Spain S. A. 2020-2021.

**Centro de gestión:** FIBHULP

**Quirce Gancedo SE, Herranz Pinto P.** New findings in asthma, allergy and atopic dermatitis. Omnix Pharma S. L. 2018-Ongoing.

**Centro de gestión:** FIBHULP

**Rodríguez Pérez MR.** Contrato garantía juvenil técnico laboratorio (PEJ2019\_TL/BMD\_12199). CM. 2020-2021.

**Centro de gestión:** FIBHULP

**Rodríguez Pérez MR.** Desarrollo de un programa formativo de formación en investigación en centros de trabajo. Colegio Valle del Miro. 2016-Ongoing.

**Centro de gestión:** FIBHULP

**Rodríguez Pérez MR.** Evaluación de la capa-

dad alérgica de productos alimentarios mediante test de activación de basófilos y sensibilización cutánea con alimentos. Angulas Aguinaga S. A. U. 2018-Ongoing.

**Centro de gestión:** FIBHULP

### Cibers y Retics

**Caballero Molina MT.** Centro de Investigación Biomédica en Red de Enfermedades Raras - CIBERER (CB06/07/1033). ISCIII. [31/12/2020]:

**Centro de gestión:** FIBHULP

### Ensayos clínicos

**Caballero Molina, MT.** BCX7353-302: un estudio fase 3, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de dos dosis diferentes de BCX7353 como tratamiento oral para la prevención de ataques en pacientes con angioedema hereditario.

**Tipo:** Clinical Trial, phase III.

**Código HULP:** Appendix 2 4984.

**Código de protocolo patrocinado:** BCX7353-302.

**Patrocinado por:** Biocryst Pharmaceuticals Inc.

**Fecha de firma:** 19/02/2020

**Caballero Molina, MT.** Estudio en fase III, multicéntrico, aleatorizado, controlado con placebo, doble ciego para evaluar la efica-

cia y la seguridad de lanadelumab para la prevención contra las crisis agudas de angioedema no histaminérgico con inhibidor de C1 (C1-INH) normal y angioedema adquirido debido a déficit de C1-INH.

**Tipo:** Clinical Trial, phase III.

**Código HULP:** 5550.

**Código de protocolo patrocinado:** SHP643-303.

**Patrocinado por:** Dyax Corp.

**Fecha de firma:** 18/11/2020

**Lluch Bernal, MM.** Estudio de fase II para evaluar la tolerabilidad, seguridad y eficacia de la inmunoterapia sublingual en pacientes con alergia al polen de gramíneas.

**Tipo:** Clinical Trial, phase II.

**Código HULP:** 5553.

**Código de protocolo patrocinado:** SL-51A.

**Patrocinado por:** Roxall Medicina España S.A (Bial Industrial Farmacéutica S.A.).

**Fecha de firma:** 10/09/2020

**Quirce Gancedo, SE.** Real world effectiveness study of mepolizumab in severe eosinophilic asthma in Spain. Redes study.

**Tipo:** Study, phase EPA-OD.

**Código HULP:** PI-3885.

**Código de protocolo patrocinado:** GLA-MEP-2019-01.

**Patrocinado por:** Glaxosmithkline S.A.

**Fecha de firma:** 09/01/2020

### Patentes y marcas

**Valenta R, Constantin C, Quirce Gancedo,**

**SE,** inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

**Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA,** authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.



**Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S,** inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 [Publication Number pending]; 2016 September 06.

**del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA,** inventors; FIIS-FJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees. In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.